Journal Home
Search for

Volume 183, Issue 1, Pages 21-26 (January 2010)


View previous. 11 of 122 View next.

The Impact of Male Circumcision on HIV Transmission

Sean M. Doylea, James G. Kahnb, Nap Hosangd, Peter R. CarrollacCorresponding Author Informationemail address

Received 2 January 2009 published online 13 November 2009.

Purpose

Adult male circumcision is currently being implemented as an HIV prevention strategy worldwide. We reviewed the literature on adult male circumcision in the prevention of HIV.

Materials and Methods

A MEDLINE® search was used to identify current literature addressing HIV and male circumcision. The data from that literature were reviewed and summarized.

Results

Three randomized, controlled trials demonstrate that circumcising adult males reduces the incidence of HIV by 50% to 60%. Adult male circumcision does not seem to have an adverse impact on sexual function. Epidemiological and economic modeling suggests that adult male circumcision can potentially be a highly cost-effective strategy for HIV prevention.

Conclusions

Safe, high quality, low cost adult male circumcision services should be made available to regions with a high HIV incidence as part of a comprehensive HIV prevention package.

Key Wordscircumcision, male, HIV

a Department of Urology, Philip R. Lee Institute for Health Policy Studies, University of California, Berkeley, Berkeley, California

b Department of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, California

c UCSF/Helen Diller Family Comprehensive Cancer Center, University of California, Berkeley, Berkeley, California

d School of Public Health, University of California, Berkeley, Berkeley, California

Corresponding Author InformationCorrespondence: Department of Urology, University of California, San Francisco, Box 1695, San Francisco, California 94143-1695 (telephone: 415-353-7098; FAX: 415-353-9932)

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 404 and 405.

 Nothing to disclose.

 Financial interest and/or other relationship with the National Institutes of Health, Blue Wolf Communications, Varian Medical Systems and AstraZeneca.

PII: S0022-5347(09)02462-8

doi:10.1016/j.juro.2009.09.030


View previous. 11 of 122 View next.